Table 3. Synopsis of patient data.

Patient characteristics (top), target and effector cell content (center) and specific antibody binding capacity for CD3, CD19, CD20 and CD33 of malignant cells in the peripheral blood as determined with the QIFIKIT (Dako) (bottom).

		Patient 1 (green)	Patient 2 (red)	Patient 3 (blue)	Patient 4 (yellow)	Patient 5 (purple)
Gender		Male	Male	Male	Female	Male
Age		19 years	86 years	78 years	67 years	52 years
Diagnosis		Mixed phenotype acute leukemia (MPAL (NOS))	CD19-positive NHL with leukemic progression	B-CLL	Relapsed B-CLL	B-CLL
Blast titer		93.4% blasts in BM at diagnosis	58% of lymphocytes in the PB are CD19-positive	29,000 B-CLL cells/μL	65% lymphocytes in the PB (9% atypical)	42% lymphocytes in the PB
Case history		newly diagnosed	newly diagnosed	newly diagnosed	4 years prior: 6x MabThera® plus fludarabine and cyclophosphamide > CR	newly diagnosed
% CD19+ in PBMCs		94.8	21	89.8	68.8	73.2
% CD3+ in PBMCs		0.8	56.1	6.8	16.6	8.6
Specific antibody binding capacity (SABC) of tumour cells in the peripheral blood	CD3	211	n.d.	n.d.	n.d.	n.d.
	CD19	8,400 ± 2,800	14,600 ± 7,700	9,600 ± 500	6,500 ± 1,700	7,600 ± 1,900
	CD20	0	19,400 ± 2,200	4,000 ± 100	1,800 ± 300	3,900 ± 1,200
	CD33	317	n.d.	n.d.	n.d.	n.d.